Clinical trial
A Randomized, Double-Blind Phase I Study to Evaluate Topically Applied WBI-1001 Cream in Patients With Psoriasis.
NCT00830817 is registered in ClinicalTrials.gov with Welichem Biotech Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind Phase I Study to Evaluate Topically Applied WBI-1001 Cream in Patients With Psoriasis.
- Lead sponsor
- Welichem Biotech Inc.
- Phase
- Observational
- Overall status
- Completed
- Start date
- July 31, 2007
- Completion date
- June 30, 2008
- Enrollment
- 36 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.